Results 191 to 200 of about 113,609 (263)

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

open access: yesVIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf   +5 more
wiley   +1 more source

Angiogenesis‐associated immune genes as prognostic markers and predictors of immunotherapy response in pancreatic ductal adenocarcinoma

open access: yesVIEW, EarlyView.
Pancreatic ductal adenocarcinoma exhibits marked angiogenic and immune heterogeneity. We identified 28 angiogenesis‐associated immune genes and developed a seven‐gene AIGScore model comprising FGF2, ADGRB3, MMP2, TYMP, VASH1, VEGFD, and ITGAV. A high AIGScore was associated with poor survival, an immunosuppressive tumor microenvironment, and reduced ...
Qing Chang   +4 more
wiley   +1 more source

CD19 CAR T cells for B-ALL with EMD. [PDF]

open access: yesBlood Adv
Llaurador Caraballo G, Steffin D.
europepmc   +1 more source

Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT γδ T cells represent an increasingly important subset of T lymphocytes in the immune response to cancer and as a platform for novel immunotherapies. The aim of this review is to synthesize recent insights into the biology and advances in therapeutic applications of γδ T cells in cutaneous malignancies, especially melanoma, within a framework ...
Simo Du   +9 more
wiley   +1 more source

BATF3 regulates differentiation of CD8<sup>+</sup> T lymphocytes and memory differentiation program. [PDF]

open access: yesLife Sci Alliance
Umemura K   +10 more
europepmc   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

open access: yesAllergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy